全文获取类型
收费全文 | 7442篇 |
免费 | 292篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 150篇 |
妇产科学 | 47篇 |
基础医学 | 979篇 |
口腔科学 | 150篇 |
临床医学 | 352篇 |
内科学 | 2307篇 |
皮肤病学 | 51篇 |
神经病学 | 464篇 |
特种医学 | 283篇 |
外科学 | 1134篇 |
综合类 | 32篇 |
预防医学 | 192篇 |
眼科学 | 41篇 |
药学 | 513篇 |
中国医学 | 55篇 |
肿瘤学 | 994篇 |
出版年
2023年 | 26篇 |
2022年 | 18篇 |
2021年 | 95篇 |
2020年 | 55篇 |
2019年 | 77篇 |
2018年 | 99篇 |
2017年 | 72篇 |
2016年 | 107篇 |
2015年 | 118篇 |
2014年 | 166篇 |
2013年 | 224篇 |
2012年 | 386篇 |
2011年 | 440篇 |
2010年 | 239篇 |
2009年 | 246篇 |
2008年 | 435篇 |
2007年 | 471篇 |
2006年 | 497篇 |
2005年 | 543篇 |
2004年 | 524篇 |
2003年 | 530篇 |
2002年 | 578篇 |
2001年 | 126篇 |
2000年 | 111篇 |
1999年 | 121篇 |
1998年 | 167篇 |
1997年 | 122篇 |
1996年 | 96篇 |
1995年 | 102篇 |
1994年 | 102篇 |
1993年 | 111篇 |
1992年 | 81篇 |
1991年 | 62篇 |
1990年 | 79篇 |
1989年 | 59篇 |
1988年 | 51篇 |
1987年 | 53篇 |
1986年 | 39篇 |
1985年 | 30篇 |
1984年 | 33篇 |
1983年 | 21篇 |
1982年 | 36篇 |
1981年 | 38篇 |
1980年 | 32篇 |
1979年 | 15篇 |
1978年 | 21篇 |
1977年 | 14篇 |
1976年 | 18篇 |
1974年 | 13篇 |
1973年 | 10篇 |
排序方式: 共有7790条查询结果,搜索用时 15 毫秒
1.
Tsuneo Saga Yuji Nakamoto Takayoshi Ishimori Takahiro Inoue Yoichi Shimizu Hiroyuki Kimura Shusuke Akamatsu Takayuki Goto Hiroyuki Watanabe Kosuke Kitaguchi Masao Watanabe Masahiro Ono Hideo Saji Osamu Ogawa Kaori Togashi 《Cancer science》2019,110(2):742-750
This first‐in‐man study was carried out to evaluate the safety, whole‐body distribution, dose estimation, and lesion accumulation of 18F‐FSU‐880, a newly developed probe targeting prostate‐specific membrane antigen. Six prostate cancer patients with known metastatic lesions underwent serial whole‐body PET/computed tomography (CT) with 18F‐FSU‐880. Blood and urine were analyzed before and after PET/CT. Accumulation of 18F‐FSU‐880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole‐body effective dose were calculated using OLINDA/EXM software was developed by Dr. Michael Stabin of Vanderbilt University, Nashville, Tennessee, USA. 18F‐FSU‐880 PET/CT could be carried out without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10?2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in 1 patient, whose bone metastases were well‐controlled and inactive. The PET/CT with 18F‐FSU‐880 could be carried out safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of 18F‐FSU‐880 PET/CT in the management of prostate cancer patients. 相似文献
2.
Shinichi Sakamoto Katsuhito Miyazawa Takahiro Yasui Taro Iguchi Misuzu Fujita Hiroaki Nishimatsu Takuro Masaki Toru Hasegawa Hatsuki Hibi Takashi Arakawa Ryosuke Ando Yoshinari Kato Noritaka Ishito Satoshi Yamaguchi Ryoji Takazawa Masao Tsujihata Makoto Taguchi Koichiro Akakura Akira Hata Tomohiko Ichikawa 《International journal of urology》2019,26(1):96-101
3.
4.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
5.
Yoshio Sakai Masaki Miyazawa Takuya Komura Takeshi Yamada Alessandro Nasti Keiko Yoshida Hisashi Takabatake Masatoshi Yamato Taro Yamashita Tatsuya Yamashita Eishiro Mizukoshi Mai Okuzono Tuyen Thuy Bich Ho Kazunori Kawaguchi Takashi Wada Masao Honda Shuichi Kaneko 《Cancer science》2019,110(3):903-912
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with an extremely poor prognosis. Chemotherapy, such as gemcitabine (GEM), is the only treatment for PDAC patients who are not suitable for radical surgical treatment; however, its anti‐tumor efficacy is limited. In this study, we investigated the host immune system response in murine PDAC models undergoing GEM treatment. We found that PDAC tumor tissues were infiltrated with a substantial number of Gr‐1+ myeloid cells and had relatively small numbers of CD4+ and CD8+ cells. In addition, there were increased numbers of myeloid cells expressing CD11b+ and Gr‐1+ in peripheral blood. When mice with PDAC tumors in the intraperitoneal cavity or liver were treated with GEM, numbers of myeloid cells in tumor tissues and in peripheral blood decreased. In contrast, numbers of CD4+ or CD8+ cells increased. In peripheral blood, the numbers of CD8+ cells expressing interferon‐gamma (IFN‐γ) were higher in GEM‐treated mice than in untreated mice. In addition, GEM treatment in combination with myeloid cell depletion further prolonged the survival of PDAC mice. The gene expression profile of peripheral blood in myeloid cell‐depleted PDAC mice treated with GEM showed biological processes related to anti‐cancer immunity, such as natural killer cell‐mediated cytotoxicity, type I IFN signaling, and co‐stimulatory signaling for T cell activation. Thus, in PDAC murine models, GEM treatment was associated with an immune response consistent with an anti‐cancer effect, and depletion of myeloid‐lineage cells played an important role in enhancing anti‐cancer immunity associated with GEM treatment. 相似文献
6.
7.
Eriko Yanagida Hiroaki Miyoshi Mai Takeuchi Noriaki Yoshida Kazutaka Nakashima Kyohei Yamada Takeshi Umeno Yasumasa Shimasaki Takuya Furuta Masao Seto Koichi Ohshima 《Hematological oncology》2020,38(5):680-688
The interaction of CD47 and signal-regulatory protein alpha (SIRPα) induces “don't eat me signal”, leading suppression of phagocytosis. This signal can affect the clinical course of malignant disease. Although CD47 and SIRPα expression are associated with clinicopathological features in several neoplasms, the investigation for adult T-cell leukemia/lymphoma (ATLL) has not been well-documented. This study aimed to declare the association between CD47 and SIRPα expression and clinicopathological features in ATLL. We performed immunostaining on 73 biopsy samples and found that CD47 is primarily expressed in tumor cells, while SIRPα is expressed in non-neoplastic stromal cells. CD47 positive cases showed significantly higher FoxP3 (P = .0232) and lower CCR4 (P = .0214). SIRPα positive cases presented significantly better overall survival than SIRPα negative cases (P = .0132). SIRPα positive cases showed significantly HLA class I (P = .0062), HLA class II (P = .0133), microenvironment PD-L1 (miPD-L1) (P = .0032), and FoxP3 (P = .0229) positivity. In univariate analysis, SIRPα expression was significantly related to prognosis (Hazard ratio [HR] 0.470; 95% confidence interval [CI] 0.253-0.870; P = .0167], although multivariate analysis did not show SIPRα as an independent prognostic factor. The expression of SIRPα on stromal cells reflects activated immune surveillance mechanism in tumor microenvironment and induce good prognosis in ATLL. More detailed studies for gene expression or genomic abnormalities will disclose clinical and biological significance of the CD47 and SIRPα in ATLL. 相似文献
8.
Hideta Nakamura Kazuya Miyagi Mariko Otsuki Yuuri Higure Naoya Nishiyama Takeshi Kinjo Masashi Nakamatsu Shusaku Haranaga Masao Tateyama Jiro Fujita 《Internal medicine (Tokyo, Japan)》2020,59(22):2945
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor. 相似文献
9.
10.